Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 559

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 559
---
 Mexico. Kineta’s patent strategy includes filing for multiple claim sets that include both specific patent claims as well as broader based claims. This approach helps to protect the innovative science at Kineta and to protect its intellectual property. Kineta’s filing strategy includes filing for patent claims for (i) composition of matter, (ii) picture claims and sequences, (iii) product uses and indications, (iv) manufacturing and (v) pharmaceutical properties and characteristics. The table below summarizes the high-level filing strategy of Kineta’s existing patent portfolio for its VISTA related assets:

|                                      |     | VISTA                          
 patents                        
 (KVA12123)                     |
| Patent Family                        |     | KVA-001                        |
| Composition of matter                |     | Y                              |
| Methods of Manufacturing             |     | Y                              |
| Sequences/Structure                  |     | Y                              |
| Indications                          |     | Y                              |
| Specification on use (mono or combo) |     | Y                              |
| Binding characteristics              |     | Y                              |
| Immune cell regulation               |     | Y                              |
| Physiologic properties               |     | Y                              |
| Discovery Candidates                 |     | To be added on a rolling basis |

Kineta strives to protect the proprietary technologies that it believes are important to its business, including by seeking, maintaining and defending patent rights, whether developed internally or in conjunction with or in-licensedfrom third parties. Kineta also relies on trade secrets relating to its monoclonal antibodies, know-how,continuing technological innovation and in-licensingopportunities to develop, strengthen and maintain its proprietary position in the field of innate immunity and fully human antibodies. As more fully described above, as of January 31, 2025, Kineta’s patent portfolio included 14 U.S. and foreign applications, which entered national phase in 2023. Kineta also relies on trade secrets and careful monitoring of its proprietary information to protect aspects of its business that are not amenable to, or that Kineta does not consider appropriate for, patent protection. Kineta’s success will depend significantly on its ability to:

| • |     | Obtain and maintain patent and other proprietary protection for commercially important technology, inventions and 
 know-how related to its business;                                                                                 |

| • |     | Defend and enforce its patents; |

| • |     | Maintain its licenses to use intellectual property owned by third parties; and |

| • |     | Preserve the confidentiality of its trade secrets